2021
DOI: 10.1038/s41589-021-00755-0
|View full text |Cite
|
Sign up to set email alerts
|

YAP-dependent proliferation by a small molecule targeting annexin A2

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
31
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 40 publications
(34 citation statements)
references
References 42 publications
0
31
0
Order By: Relevance
“…In addition to LPA, the conventional activator of YAP, a more specific and potent YAP activator, termed PY-60, has recently been developed. PY-60 is demonstrated to robustly activates YAP transcriptional activity in vitro and in vivo by targeting annexin A2 [19]. PY-60 holds therapeutic potential in pathological conditions aggravated by insufficient cell proliferation and repair.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In addition to LPA, the conventional activator of YAP, a more specific and potent YAP activator, termed PY-60, has recently been developed. PY-60 is demonstrated to robustly activates YAP transcriptional activity in vitro and in vivo by targeting annexin A2 [19]. PY-60 holds therapeutic potential in pathological conditions aggravated by insufficient cell proliferation and repair.…”
Section: Discussionmentioning
confidence: 99%
“…Phosphorylated YAP is sequestered in the cytoplasm and degraded by ubiquitin-proteasome system (UPS). Conversely, when the Hippo pathway is inactivated, unphosphorylated YAP translocates into the nucleus where it associates with TEAD family transcription factors to regulate gene expression and promote cell proliferation [19,20]. The Hippo pathway has been demonstrated as the main locus where various pathways sensing cell density are integrated to mediate cell growth [21,22].…”
Section: Introductionmentioning
confidence: 99%
“…As Anxa2 expression and phosphor-Tyr23 are largely evaluated in various cancer types [16][17][18][19][20][21]34], this regulatory mechanism towards STAT3 somehow outstands as an assignable target for STAT3 inhibition. Anxa2 has been proven facilitating cancer progression via multiple aspects by interacting with other biomolecules, among which the Anxa2 rearrangement gene expression in cancer cells through oncogenic transcription factor like NF-κB, YAP1 in Hippo pathway and STAT3/6 [22,26]. In our previous research, (20S)G-Rh2 is indicated as a natural inhibitor for Anxa2 and depresses NF-κB activation via Anxa2-p50 subunit interaction [27,28].…”
Section: Discussionmentioning
confidence: 97%
“…Recent researches on cancers indicate that Anxa2 is over-expressed in various types of cancers, promotes cancer development, metastasis and chemo-resistance, highly associated with poor prognosis [16][17][18][19][20][21]. Detailed mechanisms are revealed that Anxa2 interacts with transcriptional factors and enhances their activation including NF-κB, STAT3/6 and YAP1 [22][23][24][25][26]. In our previous work, we have already identified Anxa2 as a cellular target of (20S) ginsenoside Rh2((20S)G-Rh2), a natural ginseng extract with anti-cancer activity, and (20S)G-Rh2 inhibited NF-κB activation by interfering Anxa2-NF-κB p50 subunit interaction [27,28].…”
Section: Introductionmentioning
confidence: 99%
“…Given the tumour-suppressive nature of Hippo signalling components and the oncogenic nature of its effector transcription co-regulators, YAP and TAZ, targeting this pathway is a compelling therapeutic strategy to subvert cancer initiation and progression [52,53]. Further delineation of the underlying mechanism regulating Hippo signalling is expected to provide new and druggable targets for exploitation in cancer therapies.…”
Section: Dysregulation Of the Hippo Pathway In Cancersmentioning
confidence: 99%